Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVA: Adjuvant BEC2/BCG Vaccination in Limited Disease SCLC
NCT00037713Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 1998
- Primary completion
- Oct 2002
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in small cell lung cancer (SCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival. Started Sep 1998; status: completed.
02
Drugs
blinatumomab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00037713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037713.